Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00292864 | Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors | PHASE1 | COMPLETED | 25 | — | — | Jan 1, 2006 | Dec 1, 2007 | Jun 7, 2012 | 6 | United States |
| Name | Type | Description |
|---|---|---|
| SNS-032 Injection | DRUG | - |
Inclusion Criteria: * Able to provide written informed consent * Advanced, progressing solid tumor that has no cure * In Stage 1, any advanced solid malignancy * In Stage 2, advanced breast cancer, melanoma, or non-small cell lung cancer (NSCLC) * Eastern Cooperative Oncology Group (ECOG) Perf...